Turkey: Turkovac COVID-19 vaccine to be tested as a BioNTech booster jab

У вашего броузера проблема в совместимости с HTML5

Follow us on Telegram:
https://t.me/s/ruptlynews

Turkey’s domestically produced COVID-19 vaccine, Turkovac, is being trialled as a booster shot for those with two doses of Pfizer-BioNTech, as seen in Ankara on Monday.
Ihsan Ates, the chief physician at Ankara State Hospital, announced that “this is a task which is at the phase 2/B study, in which we will do the Turkovac reminder dose in the volunteers who have exceeded 90 days after two doses of BioNTech.”
Health Minister Fahrettin Koca stated that the trial, which starts on Monday, will mark a ‘world-first’ in terms of administering an inactive vaccine, the Turkovac, to those who have already received two doses with a messenger RNS (mRNA) vaccine, like the vaccine developed by Pfizer-BioNTech.
The study is expected to be completed within three months with the help of a total of 1034 volunteers
Turkovac shots will be administered to adolescents as a primer dose, and pregnant women will receive the vaccine next week.

SOT, Professor Ihsan Ates, Physician at Ankara State Hospital (Turkish): “This is a task which is at the phase 2/B study in which we will apply the Turkovac booster dose in volunteers which exceeded 90 days after the two doses of BioNTech, which our Health Minister Fahrettin Koca announced and said it will start on Monday, January 24.”

SOT, Professor Ihsan Ates, Chief physician at Ankara State Hospital (Turkish): “As we have just stated in this study, we make Turkovac as a reminder dose to our volunteers who have been vaccinated with two doses of BioNTech and who have been 90 days. Our work here is open-label, meaning the volunteer will prefer the vaccine he wants, a two-armed study and a total of five centers.”

SOT, Professor Ihsan Ates, Chief physician at Ankara State Hospital (Turkish): “This study will be carried out in a total of five centers in Istanbul and Izmir under the direction of Ankara City Hospital.”

SOT, Professor Ihsan Ates, Chief physician at Ankara State Hospital (Turkish): “We said that the study will be two-armed, you know, our vaccine is produced at the Dolver factory in Sanliurfa and Kocak Farma in Tekirdag, in this study we will compare these vaccines that we have self-production in both arms.”

SOT, Professor Ihsan Ates, Chief physician at Ankara State Hospital, (Turkish): “There will be 517 volunteers for both branches and we will complete our work with a total of 1034 volunteers. We expect the work to be completed in as little as three months, but we expect it to be finished in less time.”

SOT, Professor Ihsan Ates, Chief physician at Ankara State Hospital, (Turkish): “Here, our BioNTech volunteers are waiting, and we’ll be working around 11:00. After that, our work on Turkovac will continue. In this line, we will start our Turkovac study in adolescents by the end of the week. This study will be a primary dose study. Next week we will start our Turkovac vaccination study in pregnant women.”

#Turkey #COVID #Vaccine #Turkovac

Video ID: 20220124-031

Video on Demand: https://ruptly.tv/videos/20220124-031
Contact: [email protected]

Twitter: http://twitter.com/Ruptly
Facebook: http://www.facebook.com/Ruptly